BioSpace News Archive

Drug Development

Aria Pharmaceuticals Secures Six Provisional Patents for Pipeline Candidates

Aria Pharmaceuticals secured six provisional patents to cover the lead drug candidates for its lupus, idiopathic pulmonary fibrosis and chronic kidney disease research programs.

August 30, 2022
·
2 min read
·
Alex Keown
Pfizer Invests $500K in Decentralized Collective Focused on Longevity R&D

Pfizer signaled its interest in longevity research through a new partnership -and a $500,000 investment - in a decentralized drug development program driven by VitaDAO.

August 30, 2022
·
2 min read
·
Alex Keown
Drug Development

Jounce Falls on Missed Endpoint in Phase II NSCLC Study

Jounce Therapeutics announced that a Phase II trial assessing a combination treatment for non-small cell lung cancer failed to meet its primary endpoint.

August 30, 2022
·
2 min read
·
Alex Keown
Business

With $50M, Vilya’s Peptides Aim to Transcend Cells’ Lipid Membrane

Vilya will use its funds for cutting-edge computational techniques to develop innovative drugs for difficult-to-treat diseases.

August 30, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Umoja’s Unified Approach to Exceeding the Limitations of Cell Therapy

Umoja CEO Andy Scharenberg spoke with BioSpace about the company’s unique tri-platform approach to immunotherapy which aims to attack and destroy hematologic and solid organ-based tumors.

August 30, 2022
·
9 min read
·
Heather McKenzie
Policy

Therapeutic Goods Administration Provisionally Approves Moderna’s Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia

Moderna, Inc. announced that the Therapeutic Goods Administration in Australia has granted provisional approval for its Omicron-containing bivalent booster vaccine, mRNA-1273.214 as a booster dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

August 30, 2022
·
5 min read
Verisante Technology, Inc. Announces Stock Option Grant - Aug 30, 2022

Verisante Technology, Inc. announces stock option grants. The Board of Directors of the Company has approved granting a total of 1,000,000 share options.

August 30, 2022
·
1 min read
Business

Promore Pharma Interim report January – June 2022

In August 2022, the company received a granted patent in the European Union for the use of the candidate drug ropocamptide (LL-37) for the treatment of chronic wounds.

August 30, 2022
·
5 min read
Deals

Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.

Second Sight Medical Products, Inc., a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced the completion of its merger with Nano Precision Medical, Inc.

August 30, 2022
·
7 min read
Bio NC

Asensus Surgical to Participate in the H. C. Wainwright Global Investment Conference - Aug 30, 2022

Asensus Surgical, Inc. announced that Anthony Fernando, President and Chief Executive Officer and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H. C. Wainwright 24th Annual Global Investment Conference in New York City, New York.

August 30, 2022
·
1 min read